Sequenom Says Q3 Revenue Jumps 43 Percent as Loss Narrows; Firm Ups '06 Guidance | GenomeWeb
NEW YORK (GenomeWeb News) — Sequenom today said third-quarter revenues increased 43 percent as R&D spending rose 16 percent and losses decreased by 16 percent.
 
Total receipts for the three months ended Sept. 30 increased to $6.5 million from $4.6 million year over year.
 
R&D spending increased to $3 million from $2.6 million year over year.
 
The company said losses declined to $5.3 million from $6.3 million in the year-ago period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.